Back to Archived News
National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
Tuesday, October 16, 2007
Mountainside, NJ -- National Stem Cell Holding, Inc. today announced the filing of a provisional patent application for a newly discovered group of biomaterials, derived from the company's stem cell and progenitor cell lines, that may stimulate a variety of naturally occurring physiological mechanisms that are involved with the skins ability to preserve and repair itself.
These newly discovered biomaterials appear to promote the skin's natural ability to maintain youthful tone, texture and viscoelasticity. The Company believes that further research and development will clarify indications thus far that these biomaterials may be useful for a wide variety of anti-aging products including but not limited to, cosmeceuticals, cosmetics and post surgical applications.
The anti-aging market is considerable. According to Government Accounting Office, there are 75 million Baby Boomers in the U.S. with 53 million between the ages of 40 and 50. Every day 11,000 Baby Boomers turn 50 and this trend will continue for the next 10 years. Many are concerned with looking younger, feeling younger and retaining their youth and they are commanding attention with their voices and their wallets as they will be the primary contributors to the projected $12 billion increase in money spent on anti-aging products and supplements in the next year and a half alone. By 2012, 50 percent of the population will be over age 50; People over 50 years of age control 70 percent of the financial assets in the USA and 50 percent of all discretionary income.
These statistics point to one of the biggest market opportunities in the U.S. today, the anti-aging market. Anti-aging is presently a $30 billion market. In the next three years, it is expect to grow to $70 billion and is arguably the fastest growing market in the U.S.
National Stem Cell Holding, Inc. is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Company is developing a pipeline of proprietary stem cell therapeutics with particular focus on diabetes. In addition to its work with stem cell therapeutics, the Company is also working to leverage its commercial infrastructure and product development capabilities of its wholly-owned subsidiary The Sperm Bank of NY. The Company's investigational products are focused on the improvement of the quality of life for patients and their families. The Company is headquartered in Mountainside, NJ.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements, which include, but are not limited to statements regarding: the trademark application, the ability of the biomaterials to promote tissue repair and the variety of wound care applications. All of such forward-looking statements are not guarantees of future performance. They are based on management's current expectations and are subject to risks and uncertainties that are difficult to predict and generally beyond the control of the Company, and that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: the risk that the patent application will not be granted, the risk that the analysis of future data will not warrant continuation of development; the risk that the FDA, the institutional review boards for the clinical sites or the investigators may not agree with the Company's assessment of the results and may not permit future trials; the risk that concerns may arise from additional analysis or data; and the risk that the Company may encounter other unexpected hurdles. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. National Stem Cell Holding, Inc. does not undertake any obligation to update or revise any forward-looking statements, to reflect changes to management's expectations, change in events, conditions or circumstances after the date hereof, or the occurrence of or non-occurrence of any events, new information or otherwise.
Back to Archived News